The BTK inhibitor ibrutinib was approved by the FDA in 2019 in combination with obinutuzumab in patients with CLL/SLL (Moreno et al., 2019), representing the first instance that anti-CD20 mAbs were employed in a combination treatment that does not include any standard chemotherapeutic agents. Here, BTK is linked to B-cell chronic lymphocytic leukemia.